ライフサイエンスコーパス: non-small-cell lung cancer

1 inhibitor used as second-line treatment for non-small cell lung cancer.

2 GFR) inhibitors remains a major challenge in non-small cell lung cancer.

3 ways and are associated with smoking-related non-small cell lung cancer.

4 l growth factor receptor-targeted therapy in non-small cell lung cancer.

5 (TBP) and Importin 8 (IPO8) to be stable in non-small cell lung cancer.

6 potential as a new therapeutic approach for non-small cell lung cancer.

7 ytes and peripheral blood from patients with non-small cell lung cancer.

8 ve the diagnostic accuracy of the staging of non-small cell lung cancer.

9 prognostic biomarkers of prostate cancer and non-small cell lung cancer.

10 nificantly overexpressed in SCLC compared to non-small cell lung cancer.

11 h that of PET/CT in determining the stage of non-small cell lung cancer.

12 r heterogeneity and evolution in early-stage non-small cell lung cancer.

13 18)F-FDG PET quantification in patients with non-small cell lung cancer.

14 of advanced melanoma, renal cell cancer, and non-small cell lung cancer.

15 nd KRAS are now routine in the management of non-small cell lung cancer.

16 r administering immunotherapy in early-stage non-small cell lung cancer.

17 ocetaxel in previously treated patients with non-small-cell lung cancer.

18 al activity, in patients with ALK-rearranged non-small-cell lung cancer.

19 combination therapies) for stage IIIB or IV non-small-cell lung cancer.

20 e prognostic marker for survival in resected non-small-cell lung cancer.

21 has been referred for treatment of advanced non-small-cell lung cancer.

22 benefit to a number of staging scenarios in non-small-cell lung cancer.

23 t of patients with operable locally advanced non-small-cell lung cancer.

24 n expressed by many solid tumours, including non-small-cell lung cancer.

25 ess in the treatment of EGFR mutant positive non-small-cell lung cancer.

26 handgrip, strength in patients with advanced non-small-cell lung cancer.

27 previously treated, PD-L1-positive, advanced non-small-cell lung cancer.

28 therapy (SBRT) for patients with early-stage non-small-cell lung cancer.

29 nt target for upregulation by mutant KRAS in non-small cell lung cancers.

30 Phase I/II clinical trial investigations for non-small cell lung cancers.

31 RET rearrangements are found in 1-2% of non-small-cell lung cancers.

32 , investigating adjuvant therapy in resected non-small-cell lung cancers.

33 SCO) adjuvant therapy guideline for resected non-small-cell lung cancers.

34 als were eligible for inclusion, 42 (39%) in non-small-cell lung cancer, 36 (33%) in breast cancer, 2

35 with previously treated advanced KRAS-mutant non-small cell lung cancer, addition of selumetinib to d

36 In this study, we analysed LSD1 function in non-small cell lung cancer adenocarcinomas.

37 east cancer on DCE-MRI in 65 studies and (3) non-small cell lung cancer (adenocarcinomas) from benign

38 min, exhibits efficacy in pancreatic cancer, non-small cell lung cancer and breast cancer.

39 l neoantigens were identified in early-stage non-small cell lung cancer and expressed high levels of

40 SMARCD1 was down-regulated in patients with non-small cell lung cancer and lung adenocarcinoma cell

41 e impact on tumorigenesis in mouse models of non-small cell lung cancer and melanoma, loss of both bl

42 vegetables" pattern, and stronger for other non-small cell lung cancer and never smokers for the "Am

43 Patients with inoperable stage III or IV non-small-cell lung cancer and cachexia (defined as >/=5

44 onist, on cachexia in patients with advanced non-small-cell lung cancer and cachexia.

45 cers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma.

46 ion of relapse following primary surgery for non-small-cell lung cancer and the characterization of e

47 We assessed outcomes in patients with non-small-cell lung cancer and the EGFR Thr790Met mutati

48 d the overexpression of DHX33 in a subset of non-small-cell lung cancers and in Ras-mutated human lun

49 ential immune target in melanoma, but not in non-small cell lung cancer, and implicates SPAG5 as an a

50 ar survival rates of small cell lung cancer, non-small cell lung cancer, and non-lung cancer patients

51 proval of such agents for advanced melanoma, non-small cell lung cancer, and renal cell carcinoma has

52 zumab is used in advanced melanoma, advanced non-small-cell lung cancer, and in head and neck cancer.

53 ntitumor immunity in patients with melanoma, non-small-cell lung cancer, and renal cell cancer.

54 In non-small cell lung cancer, anti-PD-1 antibodies have be

55 inhibitor resistance mechanisms.EGFR-mutant non-small cell lung cancer are often resistant to EGFR t

56 ing of forty-seven patients with early-stage non-small cell lung cancer before and after three weeks

57 0 years of age with newly diagnosed advanced non-small-cell lung cancer benefit from platinum-based c

58 Non-small-cell lung cancer biopsy specimens from 2011 to

59 d controlled trials of systemic therapies in non-small-cell lung cancer, breast cancer, colorectal ca

60 82 cluster are significantly co-repressed in non-small cell lung cancer cell lines and primary tumors

61 ule targeting reduced mitogenic signaling in non-small cell lung cancer cell lines, suggesting that t

62 tor receptor (EGFR) inhibitor, erlotinib, in Non-Small Cell Lung Cancer cell lines.

63 n vitro system to delineate their effects on non-small cell lung cancer cell proliferation and apopto

64 c, data-driven approach, utilizing 106 human non-small-cell lung cancer cell lines, was used to inter

65 elivery of siRNA to undruggable KRAS mutated non-small cell lung cancer cells would sensitize the cel

66 in nanosomes was assessed in H1299 and A549 non-small cell lung cancer cells, normal MRC9 lung fibro

67 g is recapitulated in mutant KRAS homozygous non-small-cell lung cancer cells and in vivo, in spontan

68 fic cell-autonomous addiction of KRAS-mutant non-small-cell lung cancer cells to receptor-dependent n

69 Eighty-six patients with non-small cell lung cancer, colorectal liver metastases,

70 rgeted treatments for patients with advanced non-small-cell lung cancer, especially focusing on data

71 the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx

72 73 patients with advanced non-small cell lung cancer from the prospective multicen

73 serial histologic sections from 90 archival non-small cell lung cancers from January 1, 2008, to Dec

74 , an antiprogrammed cell death-1 therapy for non-small cell lung cancer, from May 2012 to September 2

75 nib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutati

76 g cancer (HR = 2.88; log-rank, P = 0.02) and non-small cell lung cancer (HR = 2.01; log-rank, P = 0.0

77 uch as CTLA-4 and PD-1 can cure melanoma and non-small cell lung cancer in a subset of patients.

78 We report here a novel orthotopic model of non-small cell lung cancer in rats, where we have studie

79 outcomes of patients diagnosed with stage 1 non-small cell lung cancer in the NLST to a nationally r

80 Osimertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the E

81 inally identified as a prognostic marker for non-small cell lung cancer, in cerebrovascular pathogene

82 In murine models of small-cell and non-small cell lung cancers, including patient-derived x

83 that downregulation of LZTFL1 expression in non-small cell lung cancer is associated with recurrence

84 imply that resistance to targeted therapy in non-small cell lung cancer is highly dynamic, and also o

85 ncing platforms for molecular diagnostics in non-small-cell lung cancer is increasingly common, allow

86 Non-small-cell lung cancer is the leading cause of cance

87 , we evolved resistance in an ALK rearranged non-small cell lung cancer line (H3122) to a panel of 4

88 eby limiting its utility in the treatment of non-small cell lung cancer metastases in the brain.

89 ed malignant neoplasms, including metastatic non-small cell lung cancer (mNSCLC).

90 ple EGFR tyrosine kinase inhibitor-resistant non-small-cell lung cancer models.

91 ted into small cell lung cancer (n = 57) and non-small cell lung cancer (n = 33).

92 TEP-based detection of early- and late-stage non-small-cell lung cancer (n = 518 late-stage validatio

93 nd OS, respectively) in early-stage I and II non-small cell lung cancer (NSCLC) after resection.

94 egrated with these workflows, we analyzed 32 non-small cell lung cancer (NSCLC) and 22 breast cancer

95 a (SqCC) are the two predominant subtypes of non-small cell lung cancer (NSCLC) and are distinct in t

96 Dose-dependent synergy was observed in Non-Small Cell Lung Cancer (NSCLC) and Head and Neck Squ

97 one of the most frequently mutated genes in non-small cell lung cancer (NSCLC) and is commonly comut

98 on of Notch signaling is a common feature of non-small cell lung cancer (NSCLC) and is correlated wit

99 the YEATS2 gene is highly amplified in human non-small cell lung cancer (NSCLC) and is required for c

100 astasis suppressor 1 (BRMS1) is decreased in non-small cell lung cancer (NSCLC) and other solid tumor

101 lecule inhibitor directed against HuR, using non-small cell lung cancer (NSCLC) as a model.

102 edle aspiration (EBUS-TBNA) in patients with non-small cell lung cancer (NSCLC) can facilitate the se

103 d using exploratory factor analysis for 2139 non-small cell lung cancer (NSCLC) cases and 2163 freque

104 mall molecule inhibitor (HL001) that induces non-small cell lung cancer (NSCLC) cell cycle arrest and

105 ng stem cell marker Lgr6 becomes enriched in non-small cell lung cancer (NSCLC) cells during malignan

106 eliver siRNA to cytoplasm of KRAS mutant H23 Non-Small Cell Lung Cancer (NSCLC) cells for oncogene kn

107 cer effects and possible mechanisms of PL on non-small cell lung cancer (NSCLC) cells in vivo and in

108 MUC1-C induces MYC expression in KRAS mutant non-small cell lung cancer (NSCLC) cells, an effect that

109 ss of its protein (BRG1) occur frequently in non-small cell lung cancer (NSCLC) cells.

110 igenic function that drives the phenotype of non-small cell lung cancer (NSCLC) cells.

111 gration and invasion in KRAS- or EGFR-mutant non-small cell lung cancer (NSCLC) cells.

112 ine whether radiomics features measured from non-small cell lung cancer (NSCLC) change during therapy

113 Non-small cell lung cancer (NSCLC) comprises 85-90% of l

114 st-line therapy in the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK rearran

115 ntation within the tumor microenvironment in non-small cell lung cancer (NSCLC) has not yet been adeq

116 ts with breast cancer and 9634 patients with non-small cell lung cancer (NSCLC) in our regression and

117 Non-small cell lung cancer (NSCLC) is characterized by e

118 Non-small cell lung cancer (NSCLC) is heterogeneous in t

119 tumorigenicity, invasion, and metastases in non-small cell lung cancer (NSCLC) lines.

120 g CRISPR, shRNA, and expression screens in a non-small cell lung cancer (NSCLC) model.

121 p = 0.001), but the worst OS was observed in non-small cell lung cancer (NSCLC) patients (HR = 3.11,

122 ngitudinal blood samples from advanced stage non-small cell lung cancer (NSCLC) patients (n = 29) rec

123 quantitative whole-body (18)F-FDG metrics in non-small cell lung cancer (NSCLC) patients as a functio

124 -erlotinib uptake may be useful in selecting non-small cell lung cancer (NSCLC) patients for erlotini

125 response are unpredictable in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with

126 nalysis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with

127 Non-small cell lung cancer (NSCLC) patients with tumors

128 irst time, to our knowledge, in stage III-IV non-small cell lung cancer (NSCLC) patients.

129 culturing DCs with pooled sera from multiple non-small cell lung cancer (NSCLC) patients.

130 predict poor long-term survival in resected non-small cell lung cancer (NSCLC) patients.

131 uc.339 correlates with lower survival in 210 non-small cell lung cancer (NSCLC) patients.

132 tatic (18)F-FDG PET for tumor delineation in non-small cell lung cancer (NSCLC) radiation therapy pla

133 d was used on the plasma of 48 patients with non-small cell lung cancer (NSCLC) to detect EGFR mutati

134 on two independent cohorts of patients with non-small cell lung cancer (NSCLC) to investigate the pr

135 e clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with platinum

136 exome sequencing analysis of an EGFR-mutant non-small cell lung cancer (NSCLC) tumor biopsy from a p

137 Purpose To investigate whether non-small cell lung cancer (NSCLC) tumors that express h

138 dysregulated in a large percentage of human non-small cell lung cancer (NSCLC) tumors.

139 Identification of patients with early stage non-small cell lung cancer (NSCLC) with high risk of rec

140 ) imaging in determining the nodal status of non-small cell lung cancer (NSCLC) with the aim of eluci

141 e widely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have

142 own to be effective in a subset of melanoma, non-small cell lung cancer (NSCLC), and kidney cancers.

143 he definitive management of locally advanced non-small cell lung cancer (NSCLC), but long-term prospe

144 st commonly inactivated tumor suppressors in non-small cell lung cancer (NSCLC), especially in tumors

145 for the HDI-based anticancer therapeutics in non-small cell lung cancer (NSCLC), in the present study

146 he most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung can

147 Among them, 20 studies of melanoma, non-small cell lung cancer (NSCLC), or renal cell carcin

148 To improve treatment outcomes in non-small cell lung cancer (NSCLC), preclinical models t

149 nce of subtype-specific prognostic genes for non-small cell lung cancer (NSCLC), we had previously pr

150 enerated by RNA sequencing for patients with non-small cell lung cancer (NSCLC).

151 ncogenes has revolutionized the treatment of non-small cell lung cancer (NSCLC).

152 in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC).

153 n with bevacizumab in patients with advanced non-small cell lung cancer (NSCLC).

154 d with one common strategy remain unclear in non-small cell lung cancer (NSCLC).

155 telet indices and prognosis in patients with non-small cell lung cancer (NSCLC).

156 with chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC).

157 ield of the most common type of lung tumors, non-small cell lung cancer (NSCLC).

158 RNA termed GAS5-AS1 as a tumor suppressor in non-small cell lung cancer (NSCLC).

159 and metformin is an effective treatment for non-small cell lung cancer (NSCLC).

160 tant metastasis in patients with early-stage non-small cell lung cancer (NSCLC).

161 ressed and correlates with poor prognosis in non-small cell lung cancer (NSCLC).

162 ients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC).

163 ur islets represents a survival advantage in non-small cell lung cancer (NSCLC).

164 ene is frequently mutated and inactivated in non-small cell lung cancer (NSCLC).

165 n-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC).

166 d marks a drastic change in the treatment of non-small cell lung cancer (NSCLC).

167 MYC-oncogenic alterations commonly found in non-small cell lung cancer (NSCLC).

168 environment and blood serum of patients with non-small cell lung cancer (NSCLC).

169 oncogenic role in mediating tumorigenesis in non-small cell lung cancer (NSCLC).

170 activity on clinical outcomes in RT-treated non-small cell lung cancer (NSCLC).

171 potential treatment strategy for KRAS mutant non-small cell lung cancers (NSCLC) and colorectal carci

172 Non-small cell lung cancers (NSCLC) marked by EGFR mutat

173 rospective study, 36 patients with stage III non-small cell lung cancers (NSCLC), who underwent dynam

174 e-escalation trial in unresectable stage III non-small-cell lung cancer (NSCLC) (Radiation Therapy On

175 nostic Assessment (DS-GPA) for patients with non-small-cell lung cancer (NSCLC) and brain metastases.

176 ne outcomes for patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and brain metastasis.

177 metabolism, thereby selectively sensitizing non-small-cell lung cancer (NSCLC) and glioblastoma (GBM

178 idermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) are associated with p

179 for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-pacli

180 alf of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured.

181 ed or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyro

182 Outcomes after resection of stage I non-small-cell lung cancer (NSCLC) are variable, potenti

183 nts who previously received radiotherapy for non-small-cell lung cancer (NSCLC) before receiving pemb

184 ort that CLCb is specifically upregulated in non-small-cell lung cancer (NSCLC) cells and is associat

185 synthesis needed for growth and viability of non-small-cell lung cancer (NSCLC) cells.

186 n K-Ras-independent, but not K-Ras-dependent non-small-cell lung cancer (NSCLC) cells.

187 ading cause of cancer deaths worldwide, with non-small-cell lung cancer (NSCLC) constituting more tha

188 Non-small-cell lung cancer (NSCLC) demonstrates remarkab

189 Non-small-cell lung cancer (NSCLC) diagnosed in young pa

190 Purpose Multiple agents for advanced non-small-cell lung cancer (NSCLC) have been approved in

191 Non-small-cell lung cancer (NSCLC) is globally prevalent

192 e to immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 20%.

193 anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known.

194 ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK t

195 RT) -associated cardiac injury for stage III non-small-cell lung cancer (NSCLC) is unclear, but highe

196 Non-small-cell lung cancer (NSCLC) leads to a significan

197 after first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at

198 expression profiling of individual CTCs from non-small-cell lung cancer (NSCLC) patients with remarka

199 (TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients.

200 eceiving anti-PD-1 or anti-PD-L1 therapy for non-small-cell lung cancer (NSCLC) presented hair repigm

201 proved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated wi

202 juvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest sur

203 improves efficacy in the first-line advanced non-small-cell lung cancer (NSCLC) setting.

204 Here, we analyzed non-small-cell lung cancer (NSCLC) specimens and cell li

205 eded for discovery of targeted therapies for non-small-cell lung cancer (NSCLC) that are specific to

206 oint inhibitors has changed the landscape of non-small-cell lung cancer (NSCLC) therapy, with 2 appro

207 ed in both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) to try to improve inc

208 and its clinical-pathologic significance in non-small-cell lung cancer (NSCLC) was investigated.

209 Patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) who either (1) had a

210 nhibitor approved for patients with advanced non-small-cell lung cancer (NSCLC) whose epidermal growt

211 y in patients with treatment-naive, advanced non-small-cell lung cancer (NSCLC) with a programmed cel

212 the treatment of all patients with advanced non-small-cell lung cancer (NSCLC), but is most active i

213 Among patients with non-small-cell lung cancer (NSCLC), data on intratumor h

214 increasingly used to treat locally advanced non-small-cell lung cancer (NSCLC), IMRT and three-dimen

215 or locally advanced or incompletely resected non-small-cell lung cancer (NSCLC), it remains uncertain

216 have shown promise in patients with advanced non-small-cell lung cancer (NSCLC), particularly with sq

217 L1) blockade, have improved the treatment of non-small-cell lung cancer (NSCLC), supporting the premi

218 Here, in elderly patients with advanced non-small-cell lung cancer (NSCLC), we compared a standa

219 nib in patients with EGFR Thr790Met-positive non-small-cell lung cancer (NSCLC), who had progressed a

220 tical component in the care of patients with non-small-cell lung cancer (NSCLC), yet cardiac injury a

221 oncogenic transcription and tumor growth in non-small-cell lung cancer (NSCLC).

222 ate metabolism and are frequently mutated in non-small-cell lung cancer (NSCLC).

223 taxel among patients with previously treated non-small-cell lung cancer (NSCLC).

224 ient malignant pleural mesothelioma (MPM) or non-small-cell lung cancer (NSCLC).

225 rain metastases in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).

226 h previously treated, advanced or metastatic non-small-cell lung cancer (NSCLC).

227 in previously treated patients with advanced non-small-cell lung cancer (NSCLC).

228 gene rearrangements are oncogenic drivers of non-small-cell lung cancer (NSCLC).

229 LKB1) is mutated in 20-30% of patients with non-small-cell lung cancer (NSCLC).

230 rst-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC).

231 durable clinical responses in patients with non-small-cell lung cancer (NSCLC).

232 nase (ALK) gene associated with ALK-positive non-small-cell lung cancer (NSCLC).

233 ver docetaxel in previously treated advanced non-small-cell lung cancer (NSCLC).

234 patients with ALK-rearranged (ALK-positive) non-small-cell lung cancer (NSCLC).

235 atients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC).

236 predictive roles of TP53, KRAS, and EGFR in non-small-cell lung cancer (NSCLC).

237 proved as second-line treatment for advanced non-small-cell lung cancer (NSCLC).

238 X-2) has been implicated in cell invasion in non-small-cell lung cancer (NSCLC).

239 that imparts a robust anti-tumor effect for non-small-cell lung cancer (NSCLC).

240 of patients with advanced, platinum-treated non-small-cell lung cancer (NSCLC).

241 2) has been associated with worse outcome in non-small-cell lung cancer (NSCLC).

242 adaptor that we have shown is important for non-small-cell lung cancer (NSCLC).

243 systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC).

244 arget for antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).

245 tients with advanced squamous or nonsquamous non-small-cell lung cancer (NSCLC).

246 iously treated BRAF(V600E)-mutant metastatic non-small-cell lung cancer (NSCLC).

247 rove local tumor control of locally advanced non-small-cell lung cancer (NSCLC).

248 ted with platinum resistance and survival in non-small-cell lung cancer (NSCLC).

249 on mutation of LKB1, frequently occurring in non-small cell lung cancers (NSCLCs), is a predominant c

250 OHHLA, we find that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated w

251 se, and it is often genetically activated in non-small-cell lung cancers (NSCLCs) by, for instance, m

252 Non-small-cell lung cancers (NSCLCs) harboring mutations

253 We previously reported that human non-small-cell lung cancers (NSCLCs) oxidize glucose in

254 nalling pathway is frequently deregulated in non-small-cell lung cancer, often through KRAS activatin

255 Non-small cell lung cancer patients carrying oncogenic E

256 for chemotherapy combined with radiation in Non-Small Cell Lung Cancer patients for use in clinical

257 non-smoker or former light smoker, advanced non-small cell lung cancer patients of Asian origin.

258 Three hundred forty-eight non-small cell lung cancer patients underwent diagnostic

259 Methods: Three hundred forty-eight non-small cell lung cancer patients underwent diagnostic

260 ors prompt a beneficial clinical response in non-small cell lung cancer patients who harbor activatin

261 d radiomic features for somatic mutations in non-small cell lung cancer patients.

262 nd after 7-10 d of erlotinib treatment in 50 non-small cell lung cancer patients.

263 odistribution and dosimetry of (18)F-FAZA in non-small cell lung cancer patients.

264 onse on a later CT scan in erlotinib-treated non-small cell lung cancer patients.

265 clinical specimens obtained from EGFR-mutant non-small-cell lung cancer patients with acquired EGFR t

266 Non-small-cell lung cancer patients with activating epid

267 a method to quantify radiosensitivity in 134 non-small-cell lung cancer patients, by using K-Means cl

268 proven pancreatic cancer, laryngeal cancer, non-small cell lung cancer, prostate cancer, melanoma, b

269 and carboplatin-paclitaxel in patients with non-small-cell lung cancer receiving thoracic radiation.

270 vival versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expressi

271 vival according to the time interval between non-small-cell lung cancer resection and the initiation

272 efficacious when started 7 to 18 weeks after non-small-cell lung cancer resection.

273 Metastatic squamous non-small-cell lung cancer (SQ NSCLC) is a serious and l

274 patients with FGFR1-amplified squamous cell non-small-cell lung cancer (sqNSCLC; arm 1) or other sol

275 Patients who recover slowly from non-small-cell lung cancer surgery may still benefit fro

276 ighest signal was detected in a patient with non-small cell lung cancer (SUVmax, 10.9; T/B ratio, 8.4

277 radication of double-positive human NCI-H358 non-small cell lung cancer target tumors over single-pos

278 recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for eff

279 he NLST group undergoing surgery for stage 1 non-small cell lung cancer, those in the SEER-Medicare N

280 rther shown that knock-out of YAP sensitizes non-small cell lung cancer to EGFR inhibitor Erlotinib.

281 idermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been

282 The high genomic instability of non-small cell lung cancer tumors leads to the rapid dev

283 Eleven patients with inoperable non-small cell lung cancer underwent 2-5 thoracic PET/MR

284 Ten patients diagnosed with advanced non-small cell lung cancer underwent subsequent dynamic

285 patients referred for the initial staging of non-small cell lung cancer underwent whole-body imaging

286 ereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer was reviewed for developmenta

287 logically proven or radiologically suspected non-small cell lung cancer were prospectively enrolled i

288 t of platinum-based adjuvant chemotherapy in non-small-cell lung cancer were used as part of the LACE

289 ed patients who had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had

290 ublicly available gene expression dataset of non-small cell lung cancer when combined with the existi

291 ired to treat multiple brain metastases from non-small-cell lung cancer when highly active targeted t

292 le of this phenomenon occurs in ALK-positive non-small cell lung cancer, where targeted therapies are

293 ework in the specific context of EGFR-driven non-small cell lung cancer, which is commonly treated wi

294 apy in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed

295 ment-naive patients with completely resected non-small-cell lung cancer who received postoperative mu

296 n: Patients with EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases now hav

297 Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at l

298 8 years with ALK-rearranged stage IIIB or IV non-small-cell lung cancer (with at least one measurable

299 In contrast, a non-small cell lung cancer xenograft expressing a consti

300 ring a subcutaneous HER3 overexpressing H441 non-small cell lung cancer xenograft.